QS Pharma receives approval from European Medicines Agency for commercial manufacture
QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan.
Article in Medical Life Sciences News: Uniqsis FlowSyn continuous flow reactor helps simplify scale-up of API batch processes
Arcinova, a Quotient Sciences business, puchased a Uniqsis FlowSyn Continuous Flow Reator to support our drug substance capabilities.
Quotient Clinical announces second US acquisition: QS Pharma
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc.
Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.